Published since 1959, International Review of Neurobiology is a well-known series appealing to neuroscientists, clinicians, psychologists, physiologists, and pharmacologists. Led by an internationally renowned editorial board, this important serial publishes both eclectic volumes made up of timely reviews and thematic volumes that focus on recent progress in a specific area of neurobiology research. This volume reviews existing theories and current research surrounding the movement disorder Dyskinesia. Leading authors review state-of-the-art in their field of investigation and provide their views and perspectives for future research Chapters are extensively referenced to provide readers with a comprehensive list of resources on the topics covered All chapters include comprehensive background information and are written in a clear form that is also accessible to the non-specialist

Biomarkers hold immense promise for the early detection of disease. Unlike other disorders like diabetes and heart disease where a limited number of biological markers are at hand that allow the physician to come up with a reliable diagnosis, there are currently no such markers available for affective disorders. As in any other disease area a major goal is therefore the identification of early markers that can categorize subsets of subjects in a consistent manner. This will allow a more precise definition and categorization of affective disorders and in turn facilitate investigations of the pathogenesis of the diseases and enhance our ability for treatment. This edited volume will not only address the area of affective disorders but also other brain disorders that are neurological in nature, including Multiple Sclerosis and Alzheimer Disease.

Degeneration of nerve cells that control cognitive, speech, and language processes leading to linguistic impairments at various levels, from verbal utterances to individual speech sounds, could indicate signs of neurological, cognitive and psychiatric disorders such as Alzheimer’s disease (AD), Parkinson’s disease (PD), amyotrophic lateral sclerosis (ALS), dementias, depression, autism spectrum disorder, schizophrenia, etc. Currently, these disorders are diagnosed using specific clinical diagnostic criteria and neuropsychological examinations. However, speech-based biomarkers could potentially offer many advantages over current clinical standards. In addition to being objective and naturalistic, they can also be collected remotely with minimal instruction and time requirements. Furthermore, Machine Learning algorithms developed to build automated diagnostic models using linguistic features extracted from speech could aid diagnosis of patients with probable diseases from a group of normal population. To ensure that speech-based biomarkers are providing accurate measurement and can serve as effective clinical tools for detecting and monitoring disease, speech features extracted and analyzed must be systematically and rigorously evaluated. Different machine learning architectures trained to classify different types of disordered speech must also be rigorously tested and systematically compared.

This eBook is a collection of articles from a Frontiers Research Topic. Frontiers Research Topics are very popular trademarks of the Frontiers Journals Series: they are collections of at least ten articles, all centered on a particular subject. With their unique mix of varied contributions from Original Research to Review Articles, Frontiers Research Topics unify the most influential researchers, the latest key findings and historical advances in a hot research area! Find out more on how to host your own Frontiers Research Topic or contribute to one as an author by contacting the Frontiers Editorial Office: frontiersin.org/about/contact.

Biomarkers, or biological markers, are quantitative measurements that offer researchers and clinicians valuable insight into diagnosis, treatment and prognosis for many disorders and diseases. A major goal in neuroscience medical research is establishing biomarkers for disorders of the nervous system. Given the promising potential and necessity for neuroscience biomarkers, the Institute of Medicine Forum on Neuroscience and Nervous System Disorders convened a public workshop and released the workshop summary entitled Neuroscience Biomarkers and Biosignatures: Converging Technologies, Emerging Partnerships. The workshop brought together experts from multiple areas to discuss the most promising and practical arenas in neuroscience in which biomarkers will have the greatest impact. The main objective of the workshop was to identify and discuss biomarker targets that are not currently being aggressively pursued but that could have the greatest near-term impact on the rate at which new treatments are brought forward for psychiatric and neurological disorders.

Rosenberg’s Molecular and Genetic Basis of Neurologic and Psychiatric Disease, Sixth Edition: Volume One, provides a comprehensive introduction and reference to the foundations and key practical aspects relevant to neurologic and psychiatric disease. A favorite of over three generations of students, clinicians and scholars, this new edition retains and expands the informative, concise and critical tone of the first edition. This is an essential reference for general medical practitioners, neurologists, psychiatrists, geneticists, and related professionals, and for the neuroscience and neurology research community. The content covers all aspects essential to the practice of neurogenetics to inform clinical diagnosis, treatment and genetic counseling. Every chapter has been thoroughly revised or newly commissioned to reflect the latest scientific and medical advances by an international team of leading scientists and clinicians. The contents have been expanded to include disorders for which a genetic basis has been recently identified, together with abundant original illustrations that convey and clarify the key points of the text in an attractive, didactic format. Comprehensive coverage of the neurogenetic foundation of neurological and psychiatric disease Provides a detailed introduction on both the clinical and basic research implications of molecular and genetics surrounding the brain Includes new chapters on molecular genomics, CRISPR and the most recent updates in molecular genetics

Subjective cognitive decline (SCD) with self-reported concerns and mild cognitive impairment (MCI) are well-established to be at increased risk of developing Alzheimer’s disease (AD) dementia and a clinical continuum of dementia progression as a spectrum of AD. AD may develop from SCD to MCI (early MCI and late MCI) and eventually to AD. Nevertheless, until recently little was known about their pathophysiology associated with cognitive-behavioral syndrome. Although for researchers, scientists and clinicians, the pathophysiology of AD spectrum is an intriguing issue, delineating it in a clear way is far from easy. Taken together, in-depth understanding of neuroimaging-based pathology behind cognitive impairments across AD spectrum may help to develop new strategy for the early diagnosis and treatment of AD. Neuroimaging has been thought to potentially reveal the pathological mechanisms of AD progression. Individuals across AD spectrum are often associated with anatomical and functional brain alterations and cognitive impairment, most of the pathophysiology will focus primarily on the brain. To investigate brain structures and functions associated with cognition, neuroimaging will be the most appropriate tool.